Guidance

DTaP/IPV/Hib (Infanrix®-IPV +Hib or Pediacel®): PGD template

PGD template to support the national diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b vaccination programme.

This publication was withdrawn on

The DTaP/IPV/Hib (Infanrix®-IPV +Hib or Pediacel®) PGD template has expired. The national immunisation programme now recommends the hexavalent vaccine DTaP/IPV/Hib/HepB for routine childhood primary immunisation. See the DTaP/IPV/Hib/HepB PGD template and the routine immunisation programme. Remaining supplies of DTaP/IPV/Hib held may be used for administering a pre-school booster, see DTaP/IPV/Hib Booster PGD template.

Documents

Diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (DTaP/IPV/Hib): patient group direction (PGD) template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (DTaP/IPV/Hib) by currently registered nurses or paramedics. This applies to individuals from 8 weeks to under 10 years of age, in accordance to the national immunisation programme. It is valid from 15 December 2015 to 30 November 2017.

The PGD template requires further authorisation by a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of NHS England for their geographical area. The PGD is not legal or valid without this local, formal authorisation.

Adoption and governance of the use of this PGD is the responsibility of the authorising commissioning body and providers.

Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body.

These PGDs should be used with reference to the Green Book, and Summary of Product Characteristics for the vaccine.

Updates to this page

Published 7 January 2016

Sign up for emails or print this page